| Document |
Document Title |
|
JP3181589B2 |
PCT No. PCT/EP91/02493 Sec. 371 Date Oct. 27, 1993 Sec. 102(e) Date Oct. 27, 1993 PCT Filed Dec. 21, 1991 PCT Pub. No. WO92/11277 PCT Pub. Date Jul. 9, 1992Compounds of the general formula I (I) are described, in which x represents an ox...
|
|
JP2001508079A |
PCT No. PCT/EP98/00377 Sec. 371 Date Jul. 14, 1999 Sec. 102(e) Date Jul. 14, 1999 PCT Filed Jan. 13, 1998 PCT Pub. No. WO98/31702 PCT Pub. Date Jul. 23, 1998The present invention relates to certain 16-hydroxy-11-(substituted phenyl)-estr...
|
|
JP3172522B2 |
In accordance with the present invention, specific binding assays are disclosed which utilize an chemiluminescent compound, i.e., moiety, which has increased stability in aqueous solution. The chemiluminescent moiety is an ester, thioest...
|
|
JP3168542B2 |
The invention is directed to the control of cellular autophagy, cellular agglutination and the immobilization of motile cells. Such control is useful in, for example, the treatment of cancer, contraception, termination of pregnancy, remo...
|
|
JP2001506267A |
An aminosterol compound according to the following formula: wherein: R1 is a member selected from the group of: R2 is H or OH; R3 is H or OH; R4 is H or OH; and R5 is a C1 to C12 alkyl group. Preferably, R5 is a C1 to C6 alkyl group, and...
|
|
JP2001503024A |
The present invention describes new substituted 7T-(--aminoalkyl)-estratrienes of general formula (I), in which the side chain SK is a radical of partial formula (II), where m equals 4, 5 or 6; n equals 0, 1 or 2; x equals 0, 1 or 2; A i...
|
|
JP2000516209A |
Novel cationic amphiphiles are provided that facilitate transport of biologically active (therapeutic) molecules into cells. The amphiphiles contain lipophilic groups derived from steroids, from mono or dialkylamines, or from alkyl or ac...
|
|
JP2000515138A |
Novel cationic amphiphiles are provided that facilitate transport of biologically active (therapeutic) molecules into cells. By this invention, such cationic amphiphile is used in a state in which it is capable of accepting additional pr...
|
|
JP2000273099A |
To produce the subject derivative having a halogen atom at a specific position, capable of allowing various side chains to be introduced by utilizing the reactivity of the halogen atom, capable of allowing a protection step and a deprote...
|
|
JP3073803B2 |
The invention relates to the compounds: either n = 1, K = oxygen, R17 = hydroxyl, R'17 = hydrogen, ethynyl, RA = methyl, RA' = isopropyl, butyl, heptafluorobutyl, X = methylene, phenylene or phenyloxy, Y = -(CH2)7; -(CH2)8-; -(CH2)5-C ID...
|
|
JP3049504B2 |
Angiostatic steroids for use in controlling ocular hypertension are disclosed. Pharmaceutical compositions of the angiostatlc steroids and their use in treating ocular hypertension, including controlling the ocular hypertension associate...
|
|
JP3048636B2 |
PCT No. PCT/EP91/02494 Sec. 371 Date Jun. 22, 1993 Sec. 102(e) Date Nov. 1, 1993 PCT Filed Dec. 21, 1991 PCT Pub. No. WO92/11278 PCT Pub. Date Jul. 9, 1992.Novel compounds of the general formula I (I) and the pharmacologically tolerable ...
|
|
JP3038715B2 |
Inclusion complexes of hydroxypropyl, hydroxyethyl, glucosyl, maltosyl or maltotriosyl derivatives of beta - or gamma -cyclodextrin with the reduced, biooxidizable, blood-brain barrier penetrating, lipoidal forms of dihydropyridine -><- ...
|
|
JP2000503985A |
Novel potentiating steroid carbamates having the general formula (I) ST-OCONR1R2(I) wherein ST is a steroid or steroid derivative, of the structure (II) optionally containing double bonds and additional oxygen substituents; the carbamate...
|
|
JP2000080029A |
To obtain the subject medicine having excellent hair-growing activities, capable of manifesting activities such as prevention of depilation and promotion of hair-growth, and useful as a hair tonic or a hair-growing agent by including cep...
|
|
JP3009169B2 |
The invention relates to the compounds (I): in which A and B are either where R2 and R'2 are H or alkyl (C1-4), or where R3 is H or alkyl (C1-4) or acyl, and - either R17 and R'17 together form a ketone, - or R17 is hydroxyl or acyloxy a...
|
|
JP2999257B2 |
PCT No. PCT/EP91/01017 Sec. 371 Date Nov. 30, 1992 Sec. 102(e) Date Nov. 30, 1992 PCT Filed Jun. 3, 1991 PCT Pub. No. WO91/18917 PCT Pub. Date Dec. 12, 1991.The invention includes compounds of the following formula where A and B either A...
|
|
JP2999258B2 |
PCT No. PCT/EP91/01018 Sec. 371 Date Nov. 30, 1992 Sec. 102(e) Date Nov. 30, 1992 PCT Filed Jun. 3, 1991 PCT Pub. No. WO91/18918 PCT Pub. Date Dec. 12, 1991.A process for the production of 10 beta -H-11 beta -(substituted phenyl) steroid...
|
|
JP2990624B2 |
This invention provides N-long chain acyl neutral amino acid esters of the general formula (I) : wherein X represents an ester-forming residue of a sterol; COR represents a long chain acyl group having 8 to 22 carbon atoms; R<5> and R<6>...
|
|
JPH11513380A |
The instant invention involves a method of preventing androgenetic alopecia and promoting hair growth, by administering to a patient in need of such treatment, particularly individuals predisposed to androgenetic alopecia, including men ...
|
|
JPH11512434A |
Compounds of structural Formula (I), and pharmacologically acceptable salts and esters thereof possess 5 alpha -reductase inhibitory activity. These compounds inhibit 5 alpha -reductase type 1 and type 2. The compounds of structural Form...
|
|
JP2962484B2 |
The invention relates to the compounds (I): in which: - RA and RA', RB and RB' represent hydrogen or alkyl (C1-4) or form a 5- or 6-membered heterocycle optionally substituted with an alkyl (C1-3), Y represents hydrogen or steroid in whi...
|
|
JP2959839B2 |
Methods for treating sex steroid-dependent diseases by inhibiting sex steroid activity include administration of novel compounds which include an androgenic nucleus substituted at a ring carbon with at least one substituent specified her...
|
|
JP2956776B2 |
There are provided 13-alkyl-11beta-phenyl-gonanes of formula I (I) wherein Z is an oxygen atom or N-OH; R2 is alpha- or beta-position methyl or ethyl; R1 is selected from heteroaryl radicals, cycloalkyl radicals, cycloalkenyl radicals, a...
|
|
JP2953725B2 |
A 11 beta -aryl-19-norprogesterone steroid of the formula: wherein (i) R1 is H, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, OH, OC(O)CH3, or OC(O)R5 , wherein R5 is C2-8 alkyl, C2-8 alkenyl, C2-8 alkynyl or aryl, R2 is H, R3 is H, C1-4 alkyl...
|
|
JPH11507815A |
The present invention provides novel phosphonic acid-based cationic lipids of the general structure:or a salt, or solvate, or enantiomers thereof wherein; (a) R1 is a lipophilic moiety; (b) R2 is a positively charged moiety; (c) R3 is a ...
|
|
JPH11507352A |
The present invention provides novel carbamate-based cationic lipids of the general structure: or a salt, or solvate, or enantiomers thereof wherein; (a) R1, is a lipophilic moiety; (b) R2 is a positively charged moiety; (c) n is an inte...
|
|
JP2911553B2 |
Compounds of the general formula I have been described in which X, R<1>, R<2>, R<3> and R<4> have the meaning stated in the description, as well as processes for the preparation thereof, pharmaceutical products containing these compounds...
|
|
JP2848907B2 |
The invention relates to the products of formula (I): in which: - R2 and R'2 = H or methyl, - R11 = C1-18 organic radical optionally containing a hetero atom, - R17 and R'17 represent: either R17 = OH or acyloxy and in which Z : in parti...
|
|
JP2842690B2 |
PCT No. PCT/DE90/00329 Sec. 371 Date Mar. 11, 1991 Sec. 102(e) Date Mar. 11, 1991 PCT Filed May 7, 1990 PCT Pub. No. WO90/13558 PCT Pub. Date Nov. 15, 1990.A process is disclosed for the preparation of 21-bromo-4-pregnene-3,20-dione deri...
|
|
JP2834651B2 |
There is disclosed novel, therapeutically active androstane derivatives having neuromuscular blocking effect, which are substituted by a quaternary ammonium group in 16-position; pharmaceutically composition containing them; process for ...
|
|
JPH10512275A |
PCT No. PCT/US96/00055 Sec. 371 Date May 6, 1997 Sec. 102(e) Date May 6, 1997 PCT Filed Jan. 12, 1996 PCT Pub. No. WO96/22100 PCT Pub. Date Jul. 25, 1996Compounds of the formula I are inhibitors of 5 alpha -reductase and are useful alone...
|
|
JP2826884B2 |
The invention relates to the compounds (I): …… in which:… - R6 represents hydrogen, methyl, fluorine, chlorine,… - R9 and R11 form a double bond, or R9 is hydrogen or fluorine and R11 is hydrogen, hydroxyl or oxo,… - the dotted...
|
|
JP2823959B2 |
Linked nucleosides having at least one functionalized nucleoside that bears a substituent such as a steroid molecule, a reporter molecule, a non-aromatic lipophilic molecule, a reporter enzyme, a peptide, a protein, a water soluble vitam...
|
|
JPH10510813A |
Novel cationic amphiphiles are provided that facilitate transport of biologically active (therapeutic) molecules into cells. The amphiphiles contain lipophilic groups derived from steroids, from mono or dialkylamines, or from alkyl or ac...
|
|
JP2794297B2 |
Products of formula (I): in which: R1 = optionally substituted carbocyclic or heterocyclic aryl or aralkyl radical, R2 = in position alpha or beta = hydrocarbon radical of 1 to 18 carbon atoms, X = -(CH2)n- with n = 1, 2 or 4 or X = -CH=...
|
|
JPH10507176A |
The disclosed invention is a process for preparing 17-beta-substituted-androsta-3,5-dien-3-carboxylic acids from 3-halo-17-beta-substituted-androsta-3,5-dienes. The process may be performed in either of two ways: (1) the 3-halo compound ...
|
|
JP2768864B2 |
PURPOSE: To obtain a new amine compd. as an intermediate of an amine steroid useful in the treatment of medulla spinalis injury, head injury, subarachnoid hemorrhage, asthma, muscular dystrophy, skin graft rejection, septic shock, etc. C...
|
|
JP2768707B2 |
The invention relates to new 11-arylsteroid compounds, having a strong antiprogestin and a weak or nonexistent antiglucocorticoid activity, to processes for preparing said compounds and also to pharmaceutical preparations which contain t...
|
|
JP2760870B2 |
PCT No. PCT/EP89/01090 Sec. 371 Date Mar. 20, 1991 Sec. 102(e) Date Mar. 20, 1991 PCT Filed Sep. 20, 1989 PCT Pub. No. WO90/03385 PCT Pub. Date Apr. 5, 1990.New 11 beta -phenyl-14 beta H-steroids of general formula (I), where Z is an oxy...
|
|
JP2758989B2 |
PCT No. PCT/EP93/00422 Sec. 371 Date Dec. 23, 1994 Sec. 102(e) Date Dec. 23, 1994 PCT Filed Feb. 23, 1993 PCT Pub. No. WO93/18010 PCT Pub. Date Sep. 16, 1993. Benzimidazole anthelmintic agents of formula (I) and their non-toxic salts in ...
|
|
JPH10114790A |
To obtain an external preparation for skin, excellent in improvement in moisture retention of skin, capable of bettering chapped skin, comprising a pyrrolidonecarboxylic acid sterol ester or an N-pyrrolidinecarbonyl amino acid sterol est...
|
|
JP2746041B2 |
PURPOSE: To obtain the subject derivative for therapeutic agent, etc., for bone metabolic diseases such as osteoporosis, consisting of a steroid derivative containing a phosphoric acid group and capable of making a steroid compound to ac...
|
|
JP2742331B2 |
Compounds of the general formula (1> wherein X represents the residue of the A, B and C rings of a steroid, R represents a hydrogen atom or an alkyl group of 1 to 4 carbon atoms, R<14> represents a hydrogen atom a halogen atom or an alky...
|
|
JP2741286B2 |
Androgen nucleus derivatives having specified substituents at the 17 alpha position are disclosed for use as antiandrogens for the treatment of androgen-dependent diseases. In some preferred embodiments, the compound EM-250 is formulated...
|
|
JP2727127B2 |
|
|
JP2718834B2 |
|
|
JP2717792B2 |
Novel 19-nor-steroids of the formula (I) wherein the A ring is either Re is selected from the group consisting of hydrogen, acyl and optionally substituted alkyl of 1 to 6 carbon atoms, R is methyl or ethyl, R1 is selected from the group...
|
|
JPH10501233A |
Invented are 17 alpha and 17 beta -substituted aromatic A ring steroidal synthetic compounds, pharmaceutical compositions containing these compounds, and methods for using these compounds to inhibit steroid 5- alpha -reductase.
|
|
JPH09512270A |
The present invention relates to methods and compositions for the transformation of cells. In particular, compositions and methods are disclosed which include combinations of the nucleic acid of interest and polyhydroxylated or polyglyco...
|
